NCT lookup

Inclusion Criteria:

1. Participants of any sex and gender must be ≥ 18 years of age at the time of signing the informed consent.
2. Participants with eGFR ≥ 30 and \< 90 mL/min/1.73 m2 at screening
3. Participants with UACR \> 200 mg/g (22.6 mg/mmol) and \< 5000 mg/g (565 mg/mmol) at screening
4. Participants with history of HTN and a SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the randomisation visit.
5. Stable and maximum daily tolerated dose of either an ACE inhibitor or an ARB (not both) for at least 4 weeks prior to the screening visit, if not medically contraindicated.
6. Participants with:

   1. Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2.
   2. Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR \< 45 mL/min/1.73 m2.
7. Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Applicable to female participants.

Exclusion Criteria:

1. Systolic blood pressure \> 180 mmHg, or diastolic blood pressure \> 110 mmHg at screening.
2. Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months before screening
3. Serum sodium \< 135 mmol/L at the Screening Visit (values obtained within 4 weeks prior to screening or at the Screening Visit).
4. Diabetes mellitus:

   1. T1DM at the screening visit
   2. Uncontrolled T2DM at screening: HbA1C \> 10.5% (\> 91 mmol/mol)
5. New York Heart Association functional HF class IV at screening
6. Any use of mineralocorticoid receptor antagonists (such as spironolactone, eplerenone, or finerenone), aldosterone synthase inhibitors, potassium-sparing diuretics (such as triamterene or amiloride), or potassium binders (such as sodium zirconium cyclosilicate, patiromer, or sodium polystyrene sulfonate) within 4 weeks prior to screening
7. Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening HF within previous 3 months prior to randomisation.
8. Known severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history.
9. Documented history of adrenal insufficiency.
10. Any dialysis (including for acute kidney injury) within 3 months prior to the screening
11. Any acute kidney injury within 3 months prior to the screening visit.
12. Prohibited concomitant medications

• Surprise, Arizona, United States
• Hollywood, Florida, United States
• Port Charlotte, Florida, United States
• Port Orange, Florida, United States
• East Point, Georgia, United States
• Champaign, Illinois, United States
• Wichita, Kansas, United States
• Greenville, North Carolina, United States
• Jacksonville, North Carolina, United States
• New Bern, North Carolina, United States
• Columbus, Ohio, United States
• Media, Pennsylvania, United States
• East Providence, Rhode Island, United States
• Arlington, Texas, United States
• Pasadena, Texas, United States
• San Antonio, Texas, United States
• Woodbridge, Virginia, United States
• Ciudad de Buenos Aires, Argentina
• Mar del Plata, Argentina
• Rosario, Argentina
• San Nicolás, Argentina
• Sofia, Bulgaria
• Yambol, Bulgaria
• Courtice, Ontario, Canada
• Etobicoke, Ontario, Canada
• Stouffville, Ontario, Canada
• Waterloo, Ontario, Canada
• Kaohsiung City, Taiwan
• Kaohsiung City, Taiwan
• New Taipei City, Taiwan
• + 25 more on CT.gov